PepGen Overview
- Year Founded
-
2018

- Status
-
Public
- Employees
-
76

- Stock Symbol
-
PEPG

- Share Price
-
$1.27
- (As of Friday Closing)
PepGen General Information
Description
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Contact Information
Website
www.pepgen.comCorporate Office
- 321 Harrison Avenue
- 8th Floor
- Boston, MA 02118
- United States
Corporate Office
- 321 Harrison Avenue
- 8th Floor
- Boston, MA 02118
- United States
PepGen Timeline
PepGen Stock Performance
As of 14-Feb-2025, PepGen’s stock price is $1.27. Its current market cap is $41.4M with 32.6M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.27 | $1.21 | $1.16 - $19.30 | $41.4M | 32.6M | 295K | -$2.98 |
PepGen Financials Summary
As of 30-Sep-2024, PepGen has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
---|---|---|---|---|
EV | 136,748 | 52,827 | 120,176 | |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (90,021) | (84,103) | (67,698) | (27,081) |
Net Income | (87,234) | (78,626) | (69,104) | (27,281) |
Total Assets | 170,234 | 143,052 | 217,440 | 143,641 |
Total Debt | 19,040 | 20,104 | 24,534 | 0 |
PepGen Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
PepGen Comparisons
Industry
Financing
Details
PepGen Competitors (66)
One of PepGen’s 66 competitors is Antag Therapeutics, a Venture Capital-Backed company based in Copenhagen, Denmark.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Antag Therapeutics | Venture Capital-Backed | Copenhagen, Denmark | ||||
MBX Biosciences | Formerly VC-backed | Carmel, IN | ||||
Alzheon | Venture Capital-Backed | Framingham, MA | ||||
Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
Apeptico | Venture Capital-Backed | Vienna, Austria |
PepGen Patents
PepGen Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
CA-3212994-A1 | Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates | Pending | 12-Mar-2021 | ||
EP-4304628-A2 | Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates | Pending | 12-Mar-2021 | ||
EP-4304657-A2 | Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates | Pending | 12-Mar-2021 | ||
US-20240189434-A1 | Methods of treating myotonic dystrophy type 1 using peptide-oligonucleotide conjugates | Pending | 12-Mar-2021 | ||
US-20240200062-A1 | Methods of treating duchenne muscular dystrophy using peptide-oligonucleotide conjugates | Pending | 12-Mar-2021 | C12N15/113 |
PepGen Signals
PepGen Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
PepGen ESG
Risk Overview
Risk Rating
Updated May, 09, 2023
29.92 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Biotechnology
Subindustry
of 368
Rank
Percentile

PepGen FAQs
-
When was PepGen founded?
PepGen was founded in 2018.
-
Where is PepGen headquartered?
PepGen is headquartered in Boston, MA.
-
What is the size of PepGen?
PepGen has 76 total employees.
-
What industry is PepGen in?
PepGen’s primary industry is Biotechnology.
-
Is PepGen a private or public company?
PepGen is a Public company.
-
What is PepGen’s stock symbol?
The ticker symbol for PepGen is PEPG.
-
What is the current stock price of PepGen?
As of 14-Feb-2025 the stock price of PepGen is $1.27.
-
What is the current market cap of PepGen?
The current market capitalization of PepGen is $41.4M.
-
Who are PepGen’s competitors?
Antag Therapeutics, MBX Biosciences, Alzheon, Sorrento Therapeutics, and Apeptico are some of the 66 competitors of PepGen.
-
What is PepGen’s annual earnings per share (EPS)?
PepGen’s EPS for 12 months was -$2.98.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »